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Disturbances in angiogenesis and vascular 
maturation in the skin are associated with 
diabetic kidney disease in type 1 diabetes
ABSTRACT
Introduction. The skin, as one of the most accessible 
tissues, is frequently used for investigations of micro-
circulation and angiogenesis. The aim of this study 
was to assess the relationship between the dermal 
microvessel density (MVD) and maturity and the pres-
ence of diabetic kidney disease (DKD) in adults with 
type 1 diabetes (T1D). Skin as the most accessible organ 
served as a model for the study of angiogenesis.
Materials and methods. 148 consecutive T1D patients 
(87 men), median age of 41 [interquartile range (IQR): 
31–49] years and diabetes duration of 21 (17–30) years, 
participated in the study. The patients were under 
the care of the Department of Internal Medicine and 
Diabetology, Poznan University of Medical Sciences. 
Diabetic kidney disease was diagnosed in patients with 
increased albuminuria and at least 10-year duration of 
diabetes or evidence of diabetic retinopathy. The skin 
biopsy was performed on distal part of lower leg, using 
a sterile, disposable 3 mm biopsy punch with plunger 
(Disposable Biopsy Punches, Integra™ Miltex®). In the 
immunohistochemical analyses, we used: anti-CD133, 
anti-CD34, anti-CD31, and anti-von Willebrand factor 
(vWF) autoantibodies. Microvessel density measure-
ment in all specimens was performed using “hot spots 
technique”. Slides were scanned using the MiraxMidi 
scanner (Carl Zeiss) and were viewed using CaseViewer 
(3DHISTECH Ltd. Budapest, Hungary). Data were ana-
lyzed using Statistica v. 13 software.
Results. In the study group 21 patients with diagnosis 
DKD+, as compared to 127 subjects withaout DKD–, 
had longer duration of diabetes [30 (IQR: 21–36) vs. 21 
(16–28) years, p = 0.002], higher prevalence of hyper-
tension [14 (67%) vs. 37 (29%), p = 0.002], lower esti-
mated glomerular filtration rate (eGFR) [66 (55–88) vs. 
94 (83–106) mL/min/1.73 m2, p < 0.001]. Median MVD 
compared between groups with and without DKD, was 
similar for CD34+ vessels/1 mm2 [123 (100–170) vs. 121 
(100–170), p = 0.775], CD133+ vessels/1 mm2 [79 (50– 
–100) vs. 79 (63–93), p = 0.823], and for CD31+ ves-
sels/1 mm2 [29 (21–46) vs. 38 (17–58), p = 0.454]. Median 
MVD vWF+ vessels/1 mm2 was lower in the group with 
than without DKD: 42 (25–54) vs. 54 (43–71), p = 0.009. 
The values given above were calculated for both lay-
ers of the dermis (papillary and reticular dermis). In 
multivariate logistic regression analysis presence of 
diabetic kidney disease was associated with lower 
median vWF+ MVD [odds ratio: 0.97 (95% confidence 
interval: 0.95–0.99), p = 0.017], with adjustment for 
age, gender, eGFR value, diabetes duration and pres-
ence of hypertension. MVD did not differ significantly 
between chronic kidney disease stages.
Conclusion. In patients with type 1 diabetes and 
diabetic kidney disease the disturbances in the an-
giogenesis and vascular maturation are present. The 
number of mature blood vessels (vWF+) in the skin 
is reduced. Disturbances in the angiogenesis occur at 
early stages of diabetic kidney disease. (Clin Diabetol 
2019; 8, 5: 231–237)
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Introduction
Diabetic kidney disease (DKD) remains the most fre-
quent cause of end-stage renal failure, despite progress 
in the treatment of diabetes. Traditionally, diagnosis 
of DKD is based on the presence of albuminuria and 
either at least 10-year duration of diabetes or evidence 
of retinopathy [1]. Hyperglycemia and glycemic fluc-
tuations, hypertension, dyslipidemia, and smoking are 
modifiable and genetics, sex, age, age at onset, and 
duration of diabetes are non-modifiable risk factors of 
DKD [2]. According to previous studies, in some people 
with DKD unpredictable progressive increase of albu-
minuria and declining glomerular filtration rate (GFR) 
has been observed [3]. Due to small and insufficient 
number of early markers of diabetic nephropathy, the 
aim of this study was to search for new prognostic 
markers of renal injury [4].
Endothelial cells (ECs) are constantly subjected to 
mechanical damage and chronic exposures to destruc-
tive factors, that lead to characteristic cell changes 
(morphology) and death (apoptosis) [5]. Terminally 
differentiated, mature ECs are characterized by a low 
proliferative potential, so endothelial progenitor cells 
(EPCs) derived from the bone marrow are involved in 
the creation and repair of blood vessels [6]. During new 
vessel formation, characteristic antigens are expressed 
on the surface of the endothelium, while some other 
antigens disappear. EPCs have properties of embryo-
nal angioblast and are characterized by expression of 
CD133 (cluster of differentiation 133) and CD34 (cluster 
of differentiation 34) (late EPCs) [7]. ECs are character-
ized by an expression of von Willebrand factor (vWF), 
CD31, CD34, but do not express immature markers as 
CD133 [8]. In our study we used immunohistochemical 
markers [CD133, CD34, CD31 (cluster of differentiation 
31) and vWF] to determine the morphological changes 
observed in dermal microangiopathy in diabetic pa-
tients.
The skin, as the most accessible organ, served 
as a model for the study of microcirculation [9, 10]. 
The objective of this study was to assess the dermal 
microvessel density (MVD) and maturity in relation to 
the presence of diabetic kidney disease in adults with 
type 1 diabetes (T1D).
Materials and methods
Patients
The study group consisted of 148 (87 men) con-
secutive patients with type 1 diabetes, median age 
(IQR) of 41 (31–49) years and diabetes duration of 21 
(17–30) years. The patients were under the care of the 
Department of Internal Medicine and Diabetology, 
Poznan University of Medical Sciences.
Inclusion criteria were: age ≥ 18 years, type 1 dia-
betes of at least 10-year duration, written informed 
consent of the patient to participate in the study. Ex-
clusion criteria were: activated partial thromboplastin 
time (APTT) > 37 s, international normalized ratio (INR) 
> 1.1, platelet count < 100 G/mm3, anticoagulant or 
antiplatelet treatment, skin disorders.
The research protocol was approved by a local Bio-
ethics Committee (No. 1064/15). The study was carried 
out in accordance with the World Medical Association 
Declaration of Helsinki.
Data collection procedures
All patients participating in the study completed 
the questionnaire containing demographic data, 
duration of diabetes and method of treatment, co-
morbidities, medication use and smoking-related data. 
Then, anthropometric measurements (body mass, 
height, waist and hip circumference, body mass index 
(BMI) = weight (kg)/squared height (m2) and blood 
pressure measurement (twice using a sphygmoma-
nometer in a sitting position after 10 minutes of rest) 
were performed.
Laboratory tests
Blood samples (10 milliliters) were taken after 10 
hours of fasting, after a period of rest, with minimum 
occlusion of the vein using an S-Monovette blood 
collection system. The serum concentrations of creati-
nine, total cholesterol, high-density lipoproteins (HDL) 
cholesterol, low-density lipoproteins (LDL) cholesterol, 
and triglycerides (TG) were measured using standard 
methods. Estimated glomerular filtration rate (eGFR) 
was calculated using the Modification of Diet in Renal 
Disease (MDRD) study equation. Glycated hemoglobin 
A1c (HbA1c) was measured in venous blood with 
competitive turbidimetric inhibition immunoassay 
method on Cobas analyzer (Roche Diagnostics, Basel, 
Switzerland) and expressed in % and IFCC (the Interna-
tional Federation of Clinical Chemistry and Laboratory 
Medicine) units (mmol/mol), the values were calibrated 
with respect to Diabetes Control and Complication 
Trial (DCCT)/National Glycohemoglobin Standardization 
Program (NGSP).
The urinary albumin excretion was assessed based 
on a 12 h urine collection, with the simultaneous 
determination of the albumin/creatinine ratio in the 
morning urine. Urinary albumin excretion from 30 
to 300 mg per day in two of the three urine collec-
tions and albumin/creatinine ratio > 30 mg/g in the 
morning urine sample was considered to be increased 
albuminuria. Diabetic kidney disease was diagnosed 
in people with increased albuminuria and a 10-year 
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duration of diabetes or shorter duration of the disease 
with coexistence of retinopathy [1]. DKD was divided 
into stages based on the result of the eGFR: stage 1 
(eGFR ≥ 90 mL/min/1.73 m2), stage 2 (eGFR 60–89 mL/ 
/min/1.73 m2), stage 3 (eGFR 30–59 mL/min/1.73 m2). 
In the investigated group there were no patients with 
more advanced chronic kidney disease (CKD) stages.
Biopsy procedure
The skin biopsy was taken on the distal part of the 
lower limb (10 cm above the lateral malleolus) after the 
skin was anesthetized with 2% lidocaine injections in 
sterile conditions. We have used a sterile, disposable 
3 mm biopsy punch with a plunger (Disposable Biopsy 
Punches, Integra™ Miltex®). The biopsy was minimally 
invasive and did not require suturing. The excised tis-
sues were fixed in Bouin solution for 24 hours at room 
temperature, and then embedded in paraffin blocks.
Immunohistochemistry
Paraffin-embedded tissue blocks were cut into 
3- to 4-µm-thick sections on a semi-automatic rotary 
microtome (Leica RM 2145, Leica Microsystems, Nuss-
loch, Germany). All of the immunohistochemical (IHC) 
analyses employed the StreptABComplex/HRP method 
modified by the use of biotinylated tyramine (Dako 
Catalyzed Signal Amplification System, Peroxidase, 
K1500, DakoCytomation A/S, Glostrup, Denmark). The 
endogenous peroxidase activity was blocked with 10% 
hydrogen peroxide. The staining IHC protocol included 
the following steps: 1) preincubation with the appropri-
ate normal goat serum in phosphate buffered saline 
for 30 minutes at room temperature, 2) incubation 
with the specific primary antibody overnight at 4°C in a 
hybridization chamber, 3) incubation with the second-
ary antibody for 60 minutes at room temperature, and 
finally 4) antigen-antibody complexes staining using 
0.5% 3-3’ diaminobenzidine (DAB; Sigma Chemical 
Co., St. Louis, MO).
All of the sections from blood vessels samples from 
an individual patient were processed in the same IHC 
experiment. The specific primary antibodies were:
 — anti-CD34 (Dako, Glostrup, Denmark; code 
M7165, diluted 1:30);
 — anti-CD133 (Novus Biologicals, Littleton, CO, USA; 
code NB300–266, diluted 1:3000);
 — anti-CD31 (Dako, Copenhagen, Denmark; code 
M0823, diluted 1:20);
 — anti-vWF (Dako; code M0616, diluted 1:30).
All tissue sections were analyzed under an AxioIm-
ager Z.1 light microscope and selected pictures were 
taken with an attached AxioCam MRc5 digital camera 
(Carl Zeiss). The negative controls consisted of speci-
mens incubated with non-immune IgG1 (X-0931, Dako, 
Gdynia, Poland) and sections for which the primary or 
secondary antibody was omitted.
Morphometric analyses
Microvessel density (MVD), defined as the mean 
number of blood vessels presented in 1 mm2 of ana-
lyzed tissue, was calculated using the “hot spots tech-
nique”. The histological preparation was viewed under 
a small magnification (20 ×) by selecting three areas 
with the highest number of blood vessels. Then, the 
vessel sections were counted under a magnification of 
40× in a selected area. The arithmetic mean of the three 
“hot spots” was calculated for microvessel number and 
subsequently calculated to 1 mm2. This procedure was 
applied separately for CD133, CD34, CD31, and vWF. 
Slides were scanned using the MiraxMidi scanner (Carl 
Zeiss) and were viewed using CaseViewer (3DHISTECH 
Ltd. Budapest, Hungary). All of the analyses were evalu-
ated independently by two scientists on coded samples 
that included positive and negative controls.
Statistical analysis
Data were analyzed using Statistica v. 13 (Stat-
Soft Inc., Tulsa, OK, USA), MedCalc v. 18.5 (MedCalc 
Software bvba, Ostend, Belgium). Patients with diag-
nosis of DKD (DKD+) and without DKD (DKD–) were 
compared using Mann-Whitney U test or Fisher exact 
test, as appropriate. Descriptive statistics and results 
of comparatory analyses are expressed as medians and 
IQR or numbers and percent. Kruskal-Wallis ANOVA was 
used to compare vWF+ MVD between stages of CKD 
(1, 2 and 3a). Multiple logistic regression was used to 
check the association between presence of CKD and 
vWF+ MVD, with adjustment for potential confound-
ers (age, gender, diabetes duration and presence of 
hypertension). P value less than 0.05 was considered 
statistically significant.
Results
The study group there were 21 T1D patients (12 
men) with DKD, median (IQR) age 44 (32–58) and 127 
(75 men) individuals with T1D without DKD, median 
age 40 (30–49) years.
DKD+ patients as compared to DKD– subjects had 
longer duration of diabetes [30 (21–36) vs. 21 (16–28) 
years, p = 0.002], more often had hypertension [14 
(67%) vs. 37 (29%), p = 0.002 and lower eGFR [66.1 
(54.7–87.0) vs. 93.5 (82.5–106.2) mL/min/1.73 m2, 
p < 0.001].
The median MVD determined by CD34 blood 
vessels per 1 mm2 dermal biopsies was 123 (100–170) 
in DKD+ group and 121 (100–154), p = 0.775 in 
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DKD– group, defined by CD133 79 (50–100) vs. 79 
(63–92), p = 0.823, by vWF 42 (25–54) vs. 54 (43–71), 
p = 0.009 and by CD31 29 (21–46) vs. 38 (17–58), 
p = 0.454 (Figure 1). The values given above were 
calculated for both layers of the dermis (papillary and 
reticular dermis). Comparison of patients DKD+ and 
DKD– is shown in Table 1.
The group contained 79 (52.7%) patients with 
CKD stage 1, 58 (39.2%) patients with CKD stage 2, 8 
(5.4%) CKD patients with stage 3a and 3 (2%) patients 
with CKD stage 3b. There were no patients with CKD 
stages 4 and 5. Comparison of MVD defined by vWF+ 
in groups of patients depending on the CKD stage is 
shown in Table 2.
In multivariate logistic regression analysis presence 
of diabetic kidney disease was associated with lower 
median vWF+ MVD [odds ratio (OR): 0.97 (95% confi-
dence interval {CI}: 0.95–0.99), p = 0.017]. In multivari-
ate model the results were adjusted for age, gender, 
diabetes duration and presence of hypertension.
Discussion
Angiogenesis is involved in the pathogenesis of dia-
betic kidney disease. The abnormal new vessels present 
in glomerular capillary area (Bowman’s capsule in the 
glomerular vascular pole) are dilated and the glomeru-
lar basement membrane is extremely thin. According to 
the study of Osterby et al. an “extra efferent arteriole” 
are detected in the early stages of diabetic nephropathy 
[11]. Hypertension may be another important driving 
factor in the progression of angiogenesis in diabetes 
[12]. Angiotensin-converting enzyme (ACE) inhibitors 
suppress angiogenesis in glomerulus [13]. One of the 
possible explanations is that these vessels can play the 
role as a “by-pass” to reduce intraglomerular pres-
sure [11]. Morphological effect of neovascularization 
is glomerular hypertrophy while functional effect is 
temporarily excessive filtration (increased GFR).
New blood vessels are structurally and functionally 
immature, endothelial cells are swollen, the basement 
membrane is thin. All this leads to increased perme-
Figure 1A, B. Demonstration of microvessels density (MVD) in skin biopsies of adults with type 1 diabetes. Sections were stained 
by immunohistochemistry to show the MVD defined by von Willebrand factor (vWF) (A) were obtained from representative patient 
without diabetic kidney disease (DKD–) and (B) from patient with DKD+. Notice significantly lower microvessel density defined 
by vWF in patient with DKD+. Scale bar = 50 µm
A
B
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ability and finally results in the extravasation of plasma 
protein [11]. Vascular endothelial growth factor (VEGF) 
plays the main role in this process. Vascular endothelial 
growth factor A (VEGF-A) is derived from podocytes and 
tubular epithelial cells and vascular endothelial growth 
factor receptor 2 (VEGFR-2) is expressed in glomerular 
and peritubular capillaries. Another phenomenon called 
“uncoupling of VEGF-A with NO (nitric oxide)” (a low 
NO bioavailability along with high VEGF), observed in 
the diabetic mice could potentiate the vascular perme-
ability in the glomerulus [14]. The final effect of unfa-
vorable processes is progression to renal fibrosis. Due 
to advancing fibrotic changes and loss of endothelial 
cells, podocytes, and tubular epithelial cells, the produc-
tion of VEGF is decreased and the process progresses 
to the advanced stages of chronic kidney disease [15].
VEGF reflects the pathology of neovascularization. 
The next step in understanding of the mechanisms of 
the pathology of neovascularization induced by meta-
bolic hypoxia is the possibility of assessing the maturity 
of the vessels. We evaluated the following markers of 
angiogenesis in the material from skin biopsy: CD34, 
CD133, CD31 and vWF. Previously, we have observed 
that MVD, assessed by CD34 (a marker of “late” EPCs) 
and CD133 (a marker of early EPCs), were significantly 
higher in patients with cardiac autonomic neuropathy 
Table 1. Comparison of groups of patients with type 1 diabetes in relation to diabetic kidney disease (DKD). Patients with 
diagnosis of diabetic kidney disease (DKD+) and without diagnosis of diabetic kidney disease (DKD–)
Variables DKD+ (N = 21) DKD– (N = 127) p value
Age (years) 44 (32–58) 40 (30–49) 0.226
Sex, female/male, N 9/12 52/75 1.0
Duration of diabetes (years) 30 (21–36) 21 (16–28) 0.002
Smoking, N (%) 7 (33) 36 (28) 0.61
Hypertension, N (%) 14 (67) 37 (29) 0.002
BMI [kg/m2] 24.9 (22.8–29) 25 (22–29) 0.980
HbA1c (%) 8.4 (7.0–9.3) 8.0 (7.3–8.9) 0.527
HbA1c [mmol/mol] 68.3 (53–78.1) 63.9 (56.3–73.8)
TG [mmol/l] 1.2 (1.0–1.7) 1.0 (0.8–1.4) 0.057
LDL-cholesterol [mmol/l] 2.6 (2.3–3.1) 2.6 (2.1–3.4) 0.709
HDL-cholesterol [mmol/l] 1.6 (1.3–1.9) 1.6 (1.4–2.2) 0.459
eGFR (MDRD) [ml/min./1.73 m2] 66.1 (54.7–87.9) 93.5 (82.5–106.2) < 0.001
MVD CD34+ [vessels/1 mm2] 123 (100–170) 121 (100–154) 0.775
MVD CD133+ [vessels/1 mm2] 79 (50–100) 79 (63–92) 0.823
MVD vWF+ [vessels/1 mm2] 42 (25–54) 54 (43–71) 0.009
MVD CD31+ [vessels/1 mm2] 29 (21–46) 38 (17–58) 0.454
CD34/CD31 ratio 4.1 (2.1–6.6) 2.7 (1.8–5.3) 0.148
CD133/CD31 ratio 3.0 (1.6–4.2) 1.7 (1.3–3.3) 0.093
vWF/CD31 ratio 1.4 (0.5–2.3) 1.3 (0.8–2.0) 0.583
Note: data are presented as median (interquartile range) or N (%); BMI — body mass index; CD — cluster of differentiation; eGFR — estimated glomerular 
filtration rate; HbA1c — glycated hemoglobin A1c; HDL — high-density lipoproteins; LDL — low-density lipoproteins; MDRD — Modification of Diet in Renal 
Disease; MVD — microvessel density; N — number of patients; TG — triglycerides; vWF — von Willebrand factor
Table 2. Comparison of microvessel density (MVD) defined by von Willebrand factor (vWF) in groups of patients depending 
on the chronic kidney disease (CKD) stage
CKD stage N (%) eGFR MDRD MVD vWF+ [vessels/1 mm2]
1 79 (52.7) 103.6 (96.1–114.9) 54.2 (41.7–70.8)
2 58 (39.2) 55.9 (53.1–57.5) 52.1 (37.5–70.8)
3a 8 (5.4) 55.6 (53.1–57.5) 47.9 (12.5–56.3)
3b 3 (2) 37.1 (31.1–37.8) 20.8 (0–41.7)
Note: data are presented as median (interquartile range) or N (%); p = 0.33 for comparison vWF+ MVD between groups with CKD stages 1,2, and 3a;  
p = 0.056 for comparison vWF+ MVD between groups with CKD stages 1,2, and 3 (combined); Kruskal-Wallis test; N — number of patients; eGFR — estima-
ted glomerular filtration rate; MDRD — Modification of Diet in Renal Disease
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(CAN). Also, CD34 MVD was higher in patients with 
diabetic peripheral neuropathy (DPN), as compared 
to subjects without complications [16]. These results 
support the concept that angiogenic processes are in-
volved in the pathogenesis of neuropathy and confirm 
the neurovascular nature of chronic diabetes compli-
cations. Interestingly, we did not find any relationship 
between markers of early ECs and the presence of DKD. 
In the animal model of kidney disease, local quantity 
of CD34+ capillaries were decreased with increasing 
severity of glomerular and tubulointerstitial lesions [17]. 
We did not find any data that confirm this phenomenon 
in patients with DKD.
CD133+ progenitor cells were used for the treat-
ment in an animal model of acute kidney injury (AKI). 
CD133+ cells promoted the restoration of the renal 
tissue, limiting the presence of markers of injury and 
pro-inflammatory molecules, promoted angiogenesis 
and protected against fibrosis [18]. Moreover, in the 
previous study we have found a negative correlation 
between CD31 MVD and skin auto fluorescence (AF) 
[19]. ECs are capable of undergoing endothelial to 
mesenchymal transition under the influence of trans-
forming growth factor-b1. They lose the expression 
of such antigens as CD31, von Willebrand factor, and 
vascular-endothelial cadherin and initiate the expres-
sion of mesenchymal cell antigens [a-smooth muscle 
actin (a-SMA), extra domain A fibronectin, N-cadherin, 
vimentin, fibroblast specific protein-1] [20]. Accord-
ing to previous studies, endothelial-to-mesenchymal 
transition is associated with albuminuria in diabetic 
nephropathy. In these studies, a decreased number 
of CD31+ endothelial cells and increased a-SMA ex-
pression in glomeruli of diabetic mice was observed 
[21, 22].
Von Willebrand factor (vWF) is a glycoprotein that 
is most researched in the context of its role in haemo-
stasis and von Willebrand disease (vWD). Quantitative 
and qualitative vWF changes can lead to an increased 
risk of bleeding, on the other hand it is regarded as 
risk factor for cardiovascular disease or venous throm-
boembolism [23, 24]. The study of Lenting et al. [25] 
showed that vWF plays a role in the angiogenesis, cell 
proliferation and inflammation. The storage of von 
Willebrand factor is a function of Weibel Palade bodies 
that are ultrastructural organelles found only in mature 
vascular endothelial cells [26]. We found a decreased 
number of MVD determined by vWF blood vessels per 
1 mm2 in DKD+ group. We did not observe that correla-
tion in relation to other chronic diabetic complications. 
Interestingly, we found a decreased number of mature 
vessels despite the very early stages of CKD present in 
the vast majority of patients. Lack of the association be-
tween vascular markers and eGFR suggests that altered 
expression of vascular markers denote earlier pathology 
than decreased glomerular filtration. The progression 
of chronic kidney disease is a very complex process and 
different factors may be dominant, depending on stage 
[27]. We can only speculate if this lower expression of 
mature vessels is caused by the altered angiogenesis 
and disturbances of vessel maturation as mechanisms 
involved in the development of diabetic nephropathy 
[28]. The process seems to be different than in other 
diabetic complications. In the course of neuropathy, 
excessive angiogenesis expressed by the increased 
number of MVD CD34+ and CD133+ plays a dominant 
role. The reduction of eGFR and positive albuminuria are 
already indicative of significant glomerular pathology, 
considered to be an important risk factor for ischemic 
heart disease. Perhaps at this stage, a simple marker 
that is vWF can be used to further determine the car-
diovascular risk in patients, as it is directly related to the 
diagnosis of DKD. The observed phenomenon seems to 
be interesting but requires further research to explain.
Conclusions
In patients with type 1 diabetes and diabetic 
kidney disease the disturbances in the angiogenesis 
and vascular maturation are present. The number of 
mature blood vessels (vWF+) in the skin is reduced. 
Disturbances in the angiogenesis occur at early stages 
of diabetic kidney disease.
Statement of competing interests
The above-mentioned authors declare that there 
is no conflict of interest.
Acknowledgments
The study was funded by the Poznan University of 
Medical Sciences (No. 502-14-02234382-41190) and 
scientific grant of Diabetes Poland.
REFERENCES
1. KDOQI Clinical Practice Guidelines and Clinical Practice Rec-
ommendations for Diabetes and Chronic Kidney Disease. Am 
J Kidney Dis. 2007; 49(2 Suppl 2): S12–154, doi: 10.1053/j.
ajkd.2006.12.005, indexed in Pubmed: 17276798.
2. Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic 
kidney disease. Adv Chronic Kidney Dis. 2014; 21(3): 260–266, 
doi: 10.1053/j.ackd.2014.03.009, indexed in Pubmed: 24780453.
3. Macisaac RJ, Jerums G. Diabetic kidney disease with and with-
out albuminuria. Curr Opin Nephrol Hypertens. 2011; 20(3): 
246–257, doi: 10.1097/MNH.0b013e3283456546, indexed in 
Pubmed: 21422923.
4. Fowler MJ. Microvascular and macrovascular complications of dia-
betes. Clin Diab. 2008; 26(2): 77–82, doi: 10.2337/diaclin.26.2.77.
5. Sabatier F, Camoin-Jau L, Anfosso F, et al. Circulating endothelial 
cells, microparticles and progenitors: key players towards the 
definition of vascular competence. J Cell Mol Med. 2009; 13(3): 
Anna Adamska et al., Angiogenesis and vascular maturation in the skin in DKD in type 1 diabetes
237
454–471, doi: 10.1111/j.1582-4934.2008.00639.x, indexed in 
Pubmed: 19379144.
6. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative 
progenitor endothelial cells for angiogenesis. Science. 1997; 
275(5302): 964–967, doi: 10.1126/science.275.5302.964, indexed 
in Pubmed: 9020076.
7. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and 
AC133 by circulating human CD34(+) cells identifies a population 
of functional endothelial precursors. Blood. 2000; 95(3): 952–958, 
indexed in Pubmed: 10648408.
8. Sadler JE. Biochemistry and genetics of von Willebrand factor. 
Annu Rev Biochem. 1998; 67: 395–424, doi: 10.1146/annurev.
biochem.67.1.395, indexed in Pubmed: 9759493.
9. Sandeman DD, Shore AC, Tooke JE. Relation of skin capillary 
pressure in patients with insulin-dependent diabetes mellitus 
to complications and metabolic control. N Engl J Med. 1992; 
327(11): 760–764, doi: 10.1056/NEJM199209103271103, in-
dexed in Pubmed: 1501652.
10. Khan F, Elhadd TA, Greene SA, et al. Impaired skin microvascular 
function in children, adolescents, and young adults with type 1 
diabetes. Diabetes Care. 2000; 23(2): 215–220, doi: 10.2337/
diacare.23.2.215, indexed in Pubmed: 10868834.
11. Østerby R, Hartmann A, Bangstad HJ. Structural changes in renal 
arterioles in type I diabetic patients. Diabetologia. 2002; 45(4): 
542–549, doi: 10.1007/s00125-002-0780-2, indexed in Pubmed: 
12032631.
12. Nakagawa T, Sato W, Kosugi T, et al. Abnormal angiogenesis in 
diabetic nephropathy. Diabetes. 2009; 58(7): 1471–1478, doi: 
10.2337/db09-0119, indexed in Pubmed: 19564458.
13. Joles JA, Braam B, Verhaar MC. ACE inhibition and glomerular 
repair: restructuring or regeneration? Kidney Int. 2006; 69(7): 
1105–1107, doi: 10.1038/sj.ki.5000237, indexed in Pubmed: 
16609678.
14. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide 
axis in diabetic nephropathy: an explanation for the paradoxical 
effects of VEGF in renal disease. Am J Physiol Renal Physiol. 2007; 
292(6): F1665–F1672, doi: 10.1152/ajprenal.00495.2006, indexed 
in Pubmed: 17545302.
15. Kim BS, Goligorsky MS. Role of VEGF in kidney development, 
microvascular maintenance and pathophysiology of renal dis-
ease. Korean J Intern Med. 2003; 18(2): 65–75, doi: 10.3904/ 
/kjim.2003.18.2.65, indexed in Pubmed: 12872442.
16. Adamska A, Pilacinski S, Zozulinska-Ziolkiewicz D, et al. An 
increased skin microvessel density is associated with neuro-
vascular complications in type 1 diabetes mellitus. Diab Vasc 
Dis Res. 2019 [Epub ahead of print]: 1479164119850831, doi: 
10.1177/1479164119850831, indexed in Pubmed: 31144511.
17. Masum MdA, Ichii O, Elewa YH, et al. Local CD34-positive capil-
laries decrease in mouse models of kidney disease associating 
with the severity of glomerular and tubulointerstitial lesions. BMC 
Nephrol. 2017; 18(1): 280, doi: 10.1186/s12882-017-0694-3, 
indexed in Pubmed: 28870174.
18. Aggarwal S, Grange C, Iampietro C, et al. Human CD133 renal 
progenitor cells induce erythropoietin production and limit 
fibrosis after acute tubular injury. Sci Rep. 2016; 6: 37270, doi: 
10.1038/srep37270, indexed in Pubmed: 27853265.
19. Adamska A, Araszkiewicz A, Pilacinski S, et al. Dermal microvessel 
density and maturity is closely associated with atherogenic dyslipi-
demia and accumulation of advanced glycation end products in adult 
patients with type 1 diabetes. Microvasc Res. 2019; 121: 46–51, 
doi: 10.1016/j.mvr.2018.10.002, indexed in Pubmed: 30312628.
20. Piera-Velazquez S, Jimenez SA. Endothelial to mesenchymal 
transition: role in physiology and in the pathogenesis of human 
diseases. Physiol Rev. 2019; 99(2): 1281–1324, doi: 10.1152/ 
/physrev.00021.2018, indexed in Pubmed: 30864875.
21. Peng H, Li Y, Wang C, et al. ROCK1 induces endothelial-to-
mesenchymal transition in glomeruli to aggravate albuminuria 
in diabetic nephropathy. Sci Rep. 2016; 6: 20304, doi: 10.1038/
srep20304, indexed in Pubmed: 26842599.
22. Liu F, Zhang S, Xu R, et al. Melatonin attenuates endothelial-
to-mesenchymal transition of glomerular endothelial cells via 
regulating miR-497/ROCK in diabetic nephropathy. Kidney Blood 
Press Res. 2018; 43(5): 1425–1436, doi: 10.1159/000493380, 
indexed in Pubmed: 30212830.
23. van Schie MC, van Loon JE, de Maat MPM, et al. Genetic deter-
minants of von Willebrand factor levels and activity in relation to 
the risk of cardiovascular disease: a review. J Thromb Haemost. 
2011; 9(5): 899–908, doi: 10.1111/j.1538-7836.2011.04243.x, 
indexed in Pubmed: 21342431.
24. Smith NL, Rice KM, Bovill EG, et al. Genetic variation associated 
with plasma von Willebrand factor levels and the risk of incident 
venous thrombosis. Blood. 2011; 117(22): 6007–6011, doi: 
10.1182/blood-2010-10-315473, indexed in Pubmed: 21163921.
25. Lenting PJ, Casari C, Christophe OD, et al. von Willebrand factor: the 
old, the new and the unknown. J Thromb Haemost. 2012; 10(12): 
2428–2437, doi: 10.1111/jth.12008, indexed in Pubmed: 23020315.
26. Edgell CJ, Haizlip JE, Bagnell CR, et al. Endothelium specific 
Weibel-Palade bodies in a continuous human cell line, EA.hy926. 
In Vitro Cell Dev Biol. 1990; 26(12): 1167–1172, indexed in 
Pubmed: 2079463.
27. Tsai WC, Wu HY, Peng YS, et al. Risk factors for development and 
progression of chronic kidney disease: a systematic review and 
exploratory meta-analysis. Medicine (Baltimore). 2016; 95(11): 
e3013, doi: 10.1097/MD.0000000000003013, indexed in Pub-
med: 26986114.
28. Fogo AB. Mechanisms of progression of chronic kidney disease. 
Pediatr Nephrol. 2007; 22(12): 2011–2022, doi: 10.1007/s00467-
007-0524-0, indexed in Pubmed: 17647026.
